{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:38:28Z","timestamp":1771677508764,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"DOI":"10.7759\/cureus.62379","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T14:34:23Z","timestamp":1718375663000},"source":"Crossref","is-referenced-by-count":1,"title":["Hypercalcemia Secondary to Calcitriol Production From Dual Combination Immunotherapy in Pulmonary Metastatic Melanoma"],"prefix":"10.7759","author":[{"given":"Andrew","family":"Strike","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven B","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok JD","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017, 377:1345-56. 10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga VM","year":"2016","unstructured":"Gastanaga VM, Schwartzberg LS, Jain RK, et al.. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med. 2016, 5:2091-100. 10.1002\/cam4.749","journal-title":"Cancer Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally RK","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020, 12:738. 10.3390\/cancers12030738","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal NN","year":"2022","unstructured":"Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD. Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin J Am Soc Nephrol. 2022, 17:922-33. 10.2215\/CJN.14671121","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor-associated hypercalcaemia","volume":"37","author":"Izzedine H","year":"2022","unstructured":"Izzedine H, Chazal T, Wanchoo R, Jhaveri KD. Immune checkpoint inhibitor-associated hypercalcaemia. Nephrol Dial Transplant. 2022, 37:1598-608. 10.1093\/ndt\/gfaa326","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-021-00825-4","article-title":"Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report","volume":"21","author":"Johnson K","year":"2021","unstructured":"Johnson K, Issa M, Parikh A, Monk P, Yin M, Mortazavi A, Yang Y. Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report. BMC Urol. 2021, 21:51. 10.1186\/s12894-021-00825-4","journal-title":"BMC Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.342","article-title":"1-25OH2D mediated hypercalcemia secondary to DISR from immune checkpoint inhibitors","volume":"5","author":"Disanti D","year":"2021","unstructured":"Disanti D, Marr A, Goldner WS. 1-25OH2D mediated hypercalcemia secondary to DISR from immune checkpoint inhibitors. J Endocr Soc. 2021, 5:A169-70. 10.1210\/jendso\/bvab048.342","journal-title":"J Endocr Soc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.935821","article-title":"A review of current clinical concepts in the pathophysiology, etiology, diagnosis, and management of hypercalcemia","volume":"28","author":"Tonon CR","year":"2022","unstructured":"Tonon CR, Silva TA, Pereira FW, et al.. A review of current clinical concepts in the pathophysiology, etiology, diagnosis, and management of hypercalcemia. Med Sci Monit. 2022, 28:e935821. 10.12659\/MSM.935821","journal-title":"Med Sci Monit"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041081","article-title":"Sarcoidosis: causes, diagnosis, clinical features, and treatments","volume":"9","author":"Jain R","year":"2020","unstructured":"Jain R, Yadav D, Puranik N, Guleria R, Jin JO. Sarcoidosis: causes, diagnosis, clinical features, and treatments. J Clin Med. 2020, 9:1081. 10.3390\/jcm9041081","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov AE","year":"2015","unstructured":"Mirrakhimov AE. Hypercalcemia of malignancy: an update on pathogenesis and management. N Am J Med Sci. 2015, 7:483-93.","journal-title":"N Am J Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S389591","article-title":"The chemoprotective role of vitamin D in skin cancer: a systematic review","volume":"14","author":"Sutedja EK","year":"2022","unstructured":"Sutedja EK, Arianto TR, Lesmana R, Suwarsa O, Setiabudiawan B. The chemoprotective role of vitamin D in skin cancer: a systematic review. Cancer Manag Res. 2022, 14:3551-65. 10.2147\/CMAR.S389591","journal-title":"Cancer Manag Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264175-hypercalcemia-secondary-to-calcitriol-production-from-dual-combination-immunotherapy-in-pulmonary-metastatic-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T14:34:33Z","timestamp":1718375673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264175-hypercalcemia-secondary-to-calcitriol-production-from-dual-combination-immunotherapy-in-pulmonary-metastatic-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.62379","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}